We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ATTR-CM

News List

AstraZeneca’s Alexion and Neurimmune sign antibody development deal Pharmaceutical-Technology
January 11, 2022
AstraZeneca’s Rare Disease group Alexion and Neurimmune have signed an exclusive worldwide partnership and licence agreement to develop NI006, a human monoclonal antibody.
NICE rejects Pfizer’s rare heart disease treatment Vyndaqel pharmatimes
May 13, 2021
Pfizer’s Vyndaqel has been rejected by the UK National Institute for Health and Care Excellence (NICE) as a treatment for the rare heart condition transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Pfizer receives CHMP recommendation for rare cardiomyopathy drug pharmaceutical-technology
December 17, 2019
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the authorisation of Pfizer’s Vyndaqel (tafamidis) ...
FDA approves novel treatments for heart disease europeanpharmaceuticalreview
May 09, 2019
The US Food and Drug Administration (FDA) has approved new treatments for heart disease caused by ATTR-CM in adults.
FDA agrees to review Pfizer’s NDAs for tafamidis pharmaceutical-technology
January 16, 2019
The US Food and Drug Administration (FDA) has accepted Pfizer’s two new drug applications (NDAs) for tafamidis to treat transthyretin amyloid cardiomyopathy (ATTR-CM).....